An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer — small cell carcinoma of the ovary hypercalcemic type (SCCOHT) — which strikes young women and girls, according to a new study. Ponatinib was found in TGen-led drug screens and preclinical studies to significantly delay tumor growth and reduce tumor volume in SCCOHT.